The US Food and Drug Administration approved Lumakras (sotorasib: AMG 510) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
Developed by US biotech giant Amgen (Nasdaq: AMGN), this is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for around 25% of mutations in non-small cell lung cancers. KRAS G12C mutations represent about 13% of mutations in non-small cell lung cancers, the FDA noted. Amgen’s shares closed up modest 1.1% at $237.94 on Friday.
The approval comes three months earlier than the previously-announced FDA action date of August 15. “The earlier approval, and the label, also improves Amgen’s competitive position compared to its closest rival, Mirati, by virtue of a widened time-to-market advantage,” commented SVB Leering analyst Geoffrey Porges.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze